Combined pars plana vitrectomy–scleral buckle versus pars plana vitrectomy for proliferative vitreoretinopathy

Abstract

The purpose of the study is to evaluate the surgical outcomes of combined pars plana vitrectomy-scleral buckle (PPV-SB) versus pars plana vitrectomy (PPV) for rhegmatogenous retinal detachment complicated with proliferative vitreoretinopathy (PVR). One thousand one hundred and seventy four patients with rhegmatogenous retinal detachment surgery between January 2002 and December 2013 were retrospectively reviewed. Patients with grade C PVR treated with either combined PPV-SB or PPV alone were included in the study. Study outcomes included single surgery anatomic success rate and postoperative visual outcome at 12 months postoperatively. Seventy-seven patients with grade C PVR were identified for analysis. At the end of 12-month follow-up, 80.5 % eyes (33/41) in the PPV-SB group and 58.3 % eyes (21/36) in the PPV group achieved single surgery anatomical success. In a multiple logistic regression model, none of the baseline variables (age, gender, macula status, grade of PVR, extent of detachment, presence of vitreous hemorrhage, lens status, status of high myopia) nor types of retinal detachment surgery (use of scleral buckle, barrier endolaser, 360 degree endolaser, cryopexy, retinectomy, tamponade agent, phacoemulsification) had significant effect on single surgery anatomical success. The post-treatment mean logMAR visual acuity of the PPV-SB group was 1.58 ± 0.58 and the PPV group was 1.57 ± 0.61. There was no significant difference in the postoperative visual acuity between the two groups (P = 0.849). For patients with grade C PVR, PPV-SB did not demonstrate a superiority over PPV alone in achieving single surgery anatomical success.

5-Fluorouracyl added infusion fluid in patients with recurrent rhegmatogeneous retinal detachment

“…The current treatment of RD associated with PVR is vitrectomy [1], [7], [8], [9], [10], [11], [12], [13], [14]. Several surgical techniques and use of surgical adjuvant drugs were described for the treatment of PVR [7], [8], [9], [10], [11], [12], [13], [14].…”

“…The current treatment of RD associated with PVR is vitrectomy [1], [7], [8], [9], [10], [11], [12], [13], [14]. Several surgical techniques and use of surgical adjuvant drugs were described for the treatment of PVR [7], [8], [9], [10], [11], [12], [13], [14]. Adding scleral buckle, performing membrane peeling, using retinotomy-retinectomy techniques, using heavy perfluorocarbon liquids and advanced tamponades such as silicone oil/perfluorocarbon gases are the introduced advances in surgery [7], [8], [9], [10], [11], [12], [13], [14].…”

Knockdown of Fibromodulin Inhibits Proliferation and Migration of RPE Cell via the VEGFR2-AKT Pathway

“…Evidence has indicated that RPE cells are strongly associated with the progression of PVR [ 20 , 21 ]. Accompanied by the breaking of retinal integrity, RPE cells are exposed to the vitreous which is rich of growth factors/cytokines.…”

LYTAK1 attenuates proliferation of retinal pigment epithelial cells through TGF‑β‑mediated epithelial‑mesenchymal transition via the ERK/AKT signaling pathway

“…Currently, proliferation and migration of RPE cells has an essential role in the progression of proliferative vitreoretinopathy (PVR) and other fibro-proliferative eye diseases ( 21 , 22 ). Evidence has indicated that viability of RPE cells is associated with various ophthalmic diseases through regulation of EMT molecular markers ( 22 ). Research has also demonstrated that RPE cell apoptosis is influenced by a combination of macrophages and soluble mediators in the progression of AMD ( 11 ).…”